The Committee's favorable opinion is a major step toward making Taxotere available to an underserved lung cancer patient population in the U.S. who have limited treatment options. In our trial, we found that patients treated with Taxotere had a significant improvement in survival. BSC refers to measures aimed at maintaining patient comfort, including nutritional support and control of symptoms such as nausea, vomiting, pain and shortness of breath.
Microtubules assemble and disassemble during a cell cycle.
Taxotere promotes their assembly and blocks their disassembly, thereby preventing cancer cells from dividing and resulting in cancer cell death. Taxotere was first approved in the U.S. in 1996 for the treatment of advanced breast cancer after failure of anthracycline-based therapy. Taxotere is now approved in more than 80 countries, including the U.S. and the European Union, for the treatment of advanced breast cancer after failure of prior chemotherapy. A premedication regimen with corticosteroids is recommended in order to prevent or reduce hypersensitivity and fluid retention. Taxotere is generally not appropriate therapy for patients with liver impairment.